Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics (NASDAQ: SYRE) has announced the approval of inducement stock options for three non-executive employees by its independent Compensation Committee. The grants include options to purchase 35,000 shares of common stock under the company's 2018 Equity Inducement Plan.
The stock options were approved on February 3, 2025, with a 10-year term and an exercise price of $22.65, matching Spyre's closing share price on that date. The vesting schedule includes 25% of shares vesting on the first employment anniversary, followed by monthly vesting of 1/48th of shares thereafter, contingent on continuous service with the company.
Spyre Therapeutics (NASDAQ: SYRE) ha annunciato l'approvazione di opzioni su azioni di incentivazione per tre dipendenti non esecutivi da parte del suo Comitato Indipendente per la Remunerazione. I grant includono opzioni per acquistare 35.000 azioni ordinarie nell'ambito del Piano di Incentivazione Azionaria del 2018 dell'azienda.
Le opzioni su azioni sono state approvate il 3 febbraio 2025, con un termine di 10 anni e un prezzo di esercizio di $22,65, corrispondente al prezzo di chiusura delle azioni di Spyre in quella data. Il programma di maturazione prevede che il 25% delle azioni maturi al primo anniversario di impiego, seguito da una maturazione mensile di 1/48 delle azioni successivamente, a condizione di un servizio continuativo con l'azienda.
Spyre Therapeutics (NASDAQ: SYRE) ha anunciado la aprobación de opciones sobre acciones de incentivo para tres empleados no ejecutivos por su Comité de Compensación Independiente. Las concesiones incluyen opciones para adquirir 35,000 acciones comunes bajo el Plan de Incentivo de Capital de 2018 de la empresa.
Las opciones sobre acciones fueron aprobadas el 3 de febrero de 2025, con un plazo de 10 años y un precio de ejercicio de $22.65, que coincide con el precio de cierre de las acciones de Spyre en esa fecha. El calendario de adquisición incluye que el 25% de las acciones adquiera derechos en el primer aniversario de empleo, seguido de una adquisición mensual de 1/48 de las acciones en adelante, condicionada a la permanencia continua en la empresa.
Spyre Therapeutics (NASDAQ: SYRE)는 독립 보상 위원회에 의해 세 명의 비정규직 직원에게 유도 주식 선택권의 승인을 발표했습니다. 이 보상에는 회사의 2018년 주식 유도 계획에 따라 35,000주를 구매할 수 있는 선택권이 포함되어 있습니다.
주식 선택권은 2025년 2월 3일에 승인되었으며, 10년의 기간과 $22.65의 행사 가격으로, 해당 날짜에 Spyre 주식의 종가와 일치합니다. 주식의 배분 일정은 첫 근무 기념일에 25%가 배분된 후, 이후 매달 1/48의 비율로 배분되며, 회사에 지속적으로 재직하는 조건이 붙습니다.
Spyre Therapeutics (NASDAQ: SYRE) a annoncé l'approbation d'options sur actions d'incitation pour trois employés non exécutifs par son Comité Indépendant de Rémunération. Les attributions incluent des options d'achat de 35 000 actions ordinaires dans le cadre du Plan d'Incentive d'Équité de l'entreprise de 2018.
Les options sur actions ont été approuvées le 3 février 2025, avec une durée de 10 ans et un prix d'exercice de 22,65 $, correspondant au prix de clôture de l'action de Spyre à cette date. Le calendrier d'acquisition inclut 25 % des actions acquises à l'anniversaire de la première année d'emploi, suivi d'une acquisition mensuelle de 1/48 des actions par la suite, conditionnée à un service continu au sein de l'entreprise.
Spyre Therapeutics (NASDAQ: SYRE) hat die Genehmigung von Optionsscheinen für drei nicht-executive Mitarbeiter durch sein unabhängiges Vergütungskomitee bekannt gegeben. Die Zuwendungen umfassen Optionen zum Kauf von 35.000 Stammaktien im Rahmen des Aktienverzinsungsplans des Unternehmens von 2018.
Die Aktienoptionen wurden am 3. Februar 2025 genehmigt, mit einer Laufzeit von 10 Jahren und einem Ausübungspreis von 22,65 $, was dem Schlusskurs von Spyre an diesem Datum entspricht. Der Vesting-Plan sieht vor, dass 25% der Aktien am ersten Jahrestag des Arbeitsverhältnisses fällig werden, gefolgt von einer monatlichen Vesting von 1/48 der Aktien, vorausgesetzt, die Beschäftigung beim Unternehmen bleibt kontinuierlich bestehen.
- Stock options granted at current market price ($22.65), indicating fair compensation alignment
- Four-year vesting schedule promotes employee retention
- Potential future dilution of existing shareholders through 35,000 new stock options
The stock options were granted with a 10-year term and an exercise price equal to
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-grants-of-inducement-awards-302371607.html
SOURCE Spyre Therapeutics, Inc.
FAQ
How many shares are included in Spyre Therapeutics' (SYRE) February 2025 inducement stock options grant?
What is the exercise price for SYRE's February 2025 inducement stock options?
What is the vesting schedule for Spyre Therapeutics' February 2025 stock options grant?
How long is the term of SYRE's February 2025 inducement stock options?
